世界の血漿分画市場(~2027年):製品別(免疫グロブリン、アルブミン、プロテアーゼ阻害剤、フォンウィルブランド因子、PCC)、用途別(神経、免疫、血液、リウマチ)、エンドユーザー別(臨床研究、病院&クリニック)

【英語タイトル】Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027

MarketsandMarketsが出版した調査資料(BT3042-22)・商品コード:BT3042-22
・発行会社(調査会社):MarketsandMarkets
・発行日:2022年5月20日
・ページ数:330
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
マーケッツアンドマーケッツ社は、世界の血漿分画市場規模が2022年265億ドルから2027年367億ドルまで達し、年平均6.7%成長すると予想しています。本市場調査資料では、血漿分画の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(免疫グロブリン、凝固因子濃縮物、アルブミン、プロテアーゼ阻害剤、その他)分析、用途別(神経、免疫、血液、救命治療、呼吸器)分析、エンドユーザー別(病院&クリニック、臨床研究所、学術機関)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の血漿分画市場規模:製品別(免疫グロブリン、凝固因子濃縮物、アルブミン、プロテアーゼ阻害剤、その他)
・世界の血漿分画市場規模:用途別(神経、免疫、血液、救命治療、呼吸器)
・世界の血漿分画市場規模:エンドユーザー別(病院&クリニック、臨床研究所、学術機関)
・世界の血漿分画市場規模:地域別
・競争状況
・企業情報
❖ レポートの概要 ❖

“The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period.”
Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, and neurological diseases. However high cost of plasma products and the lack of sufficient reimbursements, increasing adoption of on-demand recombinant factors, and shortage of plasma for manufacturing plasma fractionation products are expected to restrain the growth of this market to a certain extent during the forecast period.

“The hospitals and clinicssegmentis expected to dominate the market during the forecast period.”
Based on end user, the plasma fractionation market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes. In 2021, the hospitals and clinics segment accounted for the largest share of the global plasma fractionation market. The large share of this segment is attributed the improving healthcare infrastructure and growth in the number of hospitals & clinics in the emerging and established econmies. Leading players in this market are collaborating with hospitals to raise awareness about the treatment of rare diseases using plasma products and carry out clinical trials with hospital collaboration.Such initiatives by companies and hospitals are expected to drive the demand for plasma products for the treatment of various rare and life-threatening diseases such as hemophilia, PID, and COVID-19.

“The pulmonology application segment will witness the highest growth intheplasma fractionation market.”
Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the pulmonology segment is expected to register the highest CAGR during the forecast period. Immunoglobulins and protease inhibitors are the major plasma products used in the treatment of various respiratory diseases. Immunoglobulins are mainly used to prevent and treat upper and lower respiratory tract infections. In recent years, the use of protease inhibitors, such as alpha-1-antitrypsin, has increased significantly in the pulmonology segment, thus growing the market segment for pulmonology application significantly.

“North America will dominate the market during the forecast period.”
Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the leading players adopting various organic and inorganic growth strategies to strengthen their market positions. The expansion of fractionation plants with state-of-the-art technologies is a key growth strategy followed by major players in this market in the region. Leading players also focus on acquiring plasma collection centers to expand their presence in North America.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type -Tier 1: 37%, Tier 2: 23%,and Tier 3: 40%
• By Designation – C-level:32%, D-level:26%, and Others:42%
• By Region – North America:35%, Europe:25%, Asia Pacific:20%, Latin America: 12%, and the Middle East and Africa: 8%

List of Companies Profiled in the Report
• CSL (Australia)
• Grifols, S.A. (Spain)
• Shire (US)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• Biotest AG (Germany)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Bio Products Ltd. (UK)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan YuandaShuyang Pharmaceutical Co., Ltd. (China)
• KabaFusion (US)
• Centurion Pharma (Istanbul)
• ADMA Biologics, Inc. (US)
• PlasmaGenBioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)

Research Coverage:
This report provides a detailed picture of the global plasma fractionationmarket. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user,and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total plasma fractionation market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on plasma fractionation offered by the top 25 players in the plasma fractionation market. The report analyses the plasma fractionation market by product,application, end user, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionationmarket.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the plasma fractionationmarket.

❖ レポートの目次 ❖

9.3.2 UK 181
9.3.2.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK 181
TABLE 227 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 181
TABLE 228 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 229 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 230 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 182
TABLE 231 UK: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 183
9.3.3 FRANCE 183
9.3.3.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France 183
TABLE 232 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2020 183
TABLE 233 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 184
TABLE 234 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 235 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 236 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 185
TABLE 237 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 185
9.3.4 ITALY 186
9.3.4.1 Growth in the country’s geriatric population drives the market for plasma fractionation 186
TABLE 238 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018, AND 2023-E) 186
TABLE 239 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 187
TABLE 240 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 241 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 242 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 188
TABLE 243 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 188
9.3.5 SPAIN 188
9.3.5.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth 188
TABLE 244 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 189
TABLE 245 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 246 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 247 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 190
TABLE 248 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 190
9.3.6 REST OF EUROPE 190
TABLE 249 ROE: NUMBER OF HEMOPHILIA PATIENTS, BY COUNTRY, 2012–2018 191
TABLE 250 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 192
TABLE 251 ROE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 252 ROE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 253 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 193
TABLE 254 ROE: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 193

9.4 ASIA PACIFIC 193
FIGURE 29 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT 194
TABLE 255 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 195
TABLE 256 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 195
TABLE 257 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 258 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 259 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 196
TABLE 260 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 196
9.4.1 CHINA 197
9.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market growth in China 197
TABLE 261 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 198
TABLE 262 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 263 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 264 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 199
TABLE 265 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 199
9.4.2 JAPAN 199
9.4.2.1 Rising prevalence of neurological disorders and hematological diseases will support market growth in the country 199
TABLE 266 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN,
2014 VS. 2018 (IN IU/TOTAL POPULATION) 200
TABLE 267 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2020 200
TABLE 268 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 201
TABLE 269 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 270 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 271 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 202
TABLE 272 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 202
9.4.3 AUSTRALIA 202
9.4.3.1 Growing demand for plasma products for the treatment of chronic diseases to drive market growth 202
TABLE 273 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18 203
TABLE 274 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2018 (USD MILLION) 203
TABLE 275 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017–2018) 204
TABLE 276 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 204
TABLE 277 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 278 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 279 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 205
TABLE 280 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 205
9.4.4 INDIA 206
9.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth 206
TABLE 281 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2018 206
TABLE 282 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 207
TABLE 283 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 284 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 285 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 208
TABLE 286 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 208
9.4.5 VIETNAM 208
9.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth 208
TABLE 287 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 209
TABLE 288 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 289 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 290 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 210
TABLE 291 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 210
9.4.6 INDONESIA 210
9.4.6.1 Growing government initiatives to drive market growth 210
TABLE 292 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 211
TABLE 293 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 294 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 295 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 212
TABLE 296 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 212
9.4.7 MALAYSIA 213
9.4.7.1 Increasing prevalence of bleeding disorders will support the plasma fractionation market in Malaysia 213
TABLE 297 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 213
TABLE 298 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 299 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 300 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 214
TABLE 301 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 214
9.4.8 REST OF ASIA PACIFIC 215
TABLE 302 ROAPAC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 215
TABLE 303 ROAPAC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 304 ROAPAC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 305 ROAPAC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 216
TABLE 306 ROAPAC: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 216
9.5 LATIN AMERICA 217
TABLE 307 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 217
TABLE 308 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 217
TABLE 309 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 310 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 311 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 218
TABLE 312 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 219
9.5.1 BRAZIL 219
9.5.1.1 Growth of vaccine manufacturing to increase the market growth 219
TABLE 313 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 219
TABLE 314 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 315 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 316 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 220
TABLE 317 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 220
9.5.2 ROLATAM 221
TABLE 318 ROLATAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 221
TABLE 319 ROLATAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 320 ROLATAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 321 ROLATAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 222
TABLE 322 ROLATAM: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 222
9.6 MIDDLE EAST & AFRICA 223
TABLE 323 HEMOPHILIA PATIENTS IN THE MIDDLE EAST & AFRICA, BY COUNTRY,
2012–2020 223
TABLE 324 PER CAPITA CONSUMPTION OF FACTORS IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2018 224
TABLE 325 MEA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 224
TABLE 326 MEA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 225
TABLE 327 MEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 328 MEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 329 MEA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 226
TABLE 330 MEA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 226
9.6.1 TURKEY 226
9.6.1.1 Turkey dominates the plasma fractionation market in the Middle East & Africa 226
TABLE 331 TURKEY: DEMOGRAPHIC INDICATORS 227
TABLE 332 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 227
TABLE 333 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 334 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 335 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 228
TABLE 336 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 228
9.6.2 SAUDI ARABIA 229
9.6.2.1 Developments in healthcare infrastructure to support market growth 229
TABLE 337 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 229
TABLE 338 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 339 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 340 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 230
TABLE 341 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 231
9.6.3 EGYPT 231
9.6.3.1 Growing research on plasma and plasma derivatives will support market growth 231
TABLE 342 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 232
TABLE 343 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 344 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 345 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 233
TABLE 346 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 233
9.6.4 UAE 233
9.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market growth in the UAE 233
TABLE 347 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 234
TABLE 348 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 349 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 350 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 235
TABLE 351 UAE: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 235
9.6.5 REST OF THE MIDDLE EAST & AFRICA 235
TABLE 352 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST & AFRICA, 2012−2018 236
TABLE 353 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 236
TABLE 354 ROMEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION) 237
TABLE 355 ROMEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION) 237
TABLE 356 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 237
TABLE 357 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION) 238
10 COMPETITIVE LANDSCAPE 239
10.1 OVERVIEW 239
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 239
FIGURE 30 KEY PLAYER STRATEGIES IN THE PLASMA FRACTIONATION MARKET,
2018–2022 240
10.3 MARKET SHARE ANALYSIS 241
FIGURE 31 PLASMA FRACTIONATION MARKET: MARKET SHARE ANALYSIS,
2021 (TOP 5 PLAYERS) 241
TABLE 358 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION 241
10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 243
FIGURE 32 REVENUE SHARE ANALYSIS OF PLAYERS IN THE PLASMA FRACTIONATION MARKET (TOP 5) 243
10.5 COMPANY EVALUATION QUADRANT 244
10.5.1 STARS 244
10.5.2 EMERGING LEADERS 244
10.5.3 PERVASIVE PLAYERS 244
10.5.4 PARTICIPANTS 244
FIGURE 33 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT, 2021 245
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 246
10.6.1 PROGRESSIVE COMPANIES 246
10.6.2 STARTING BLOCKS 246
10.6.3 RESPONSIVE COMPANIES 246
10.6.4 DYNAMIC COMPANIES 246
FIGURE 34 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021 247
10.7 COMPETITIVE BENCHMARKING 248
10.7.1 COMPANY PRODUCT & REGIONAL FOOTPRINT (25 COMPANIES) 248
FIGURE 35 PRODUCT & REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE PLASMA FRACTIONATION MARKET 248
10.7.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 249
TABLE 359 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET (2021) 249
10.7.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 250
TABLE 360 REGIONAL REVENUE MIX: PLASMA FRACTIONATION MARKET (2021) 250
10.8 COMPETITIVE SCENARIO AND TRENDS 251
TABLE 361 PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2022 251
TABLE 362 DEALS, JANUARY 2018–APRIL 2022 252
TABLE 363 OTHER DEVELOPMENTS, JANUARY 2018–APRIL 2022 253
10.9 COMPETITIVE BENCHMARKING 254
TABLE 364 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY START-UPS/SMES 254
TABLE 365 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES] 255

11 COMPANY PROFILES 256
11.1 KEY PLAYERS 256
(Business overview, Products offered, Recent Developments, MNM view)*
11.1.1 CSL 256
TABLE 366 CSL: BUSINESS OVERVIEW 256
FIGURE 36 CSL: COMPANY SNAPSHOT (2021) 257
11.1.2 GRIFOLS, S.A. 261
TABLE 367 GRIFOLS, S.A.: BUSINESS OVERVIEW 261
FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2021) 262
11.1.3 SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED) 268
TABLE 368 SHIRE: BUSINESS OVERVIEW 268
FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 269
11.1.4 OCTAPHARMA AG 273
TABLE 369 OCTAPHARMA AG: BUSINESS OVERVIEW 273
FIGURE 39 OCTAPHARMA AG: COMPANY SNAPSHOT (2021) 273
11.1.5 KEDRION S.P.A 277
TABLE 370 KEDRION S.P.A: BUSINESS OVERVIEW 277
FIGURE 40 KEDRION S.P.A: COMPANY SNAPSHOT (2020) 277
11.1.6 LFB 281
TABLE 371 LFB: BUSINESS OVERVIEW 281
11.1.7 BIOTEST AG 284
TABLE 372 BIOTEST AG: BUSINESS OVERVIEW 284
FIGURE 41 BIOTEST AG: COMPANY SNAPSHOT (2021) 285
11.1.8 SANQUIN 288
TABLE 373 SANQUIN: BUSINESS OVERVIEW 288
FIGURE 42 SANQUIN: COMPANY SNAPSHOT (2021) 289
11.1.9 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. 291
TABLE 374 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: BUSINESS OVERVIEW 291
11.1.10 GC PHARMA 294
TABLE 375 GC PHARMA: BUSINESS OVERVIEW 294
FIGURE 43 GC PHARMA: COMPANY SNAPSHOT (2020) 294
11.1.11 BIO PRODUCTS LABORATORY LTD. 297
TABLE 376 BIO PRODUCTS LABORATORY LTD.: BUSINESS OVERVIEW 297
11.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION 300
TABLE 377 JAPAN BLOOD PRODUCTS ORGANIZATION: BUSINESS OVERVIEW 300
FIGURE 44 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2020) 300
11.1.13 EMERGENT BIOSOLUTIONS 303
TABLE 378 EMERGENT BIOSOLUTIONS: BUSINESS OVERVIEW 303
FIGURE 45 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2021) 303
11.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. 306
TABLE 379 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: BUSINESS OVERVIEW 306
11.1.15 INTAS PHARMACEUTICALS LTD. 309
TABLE 380 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW 309
FIGURE 46 INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021) 309
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11.2 OTHER COMPANIES 311
11.2.1 BHARAT SERUMS AND VACCINES LIMITED 311
11.2.2 SK PLASMA 312
11.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD. 313
11.2.4 KABAFUSION 314
11.2.5 CENTURION PHARMA 315
11.2.6 ADMA BIOLOGICS, INC. 315
11.2.7 PLASMAGEN BIOSCIENCES PVT. LTD. 316
11.2.8 VIRCHOW BIOTECH PRIVATE LIMITED 316
11.2.9 FUSION HEALTHCARE 317
11.2.10 HEMARUS THERAPEUTICS LIMITED 318
12 APPENDIX 319
12.1 DISCUSSION GUIDE 319
12.2 AVAILABLE CUSTOMIZATIONS 324
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325
12.4 RELATED REPORTS 327
12.5 AUTHOR DETAILS 328

★調査レポート[世界の血漿分画市場(~2027年):製品別(免疫グロブリン、アルブミン、プロテアーゼ阻害剤、フォンウィルブランド因子、PCC)、用途別(神経、免疫、血液、リウマチ)、エンドユーザー別(臨床研究、病院&クリニック)] (コード:BT3042-22)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の血漿分画市場(~2027年):製品別(免疫グロブリン、アルブミン、プロテアーゼ阻害剤、フォンウィルブランド因子、PCC)、用途別(神経、免疫、血液、リウマチ)、エンドユーザー別(臨床研究、病院&クリニック)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆